P673 The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study
نویسندگان
چکیده
Abstract Background Rapid infliximab (IFX) infusions have shown to be safe in adults with inflammatory bowel disease (IBD), but data on its safety paediatric IBD is limited. This study aimed assess the frequency and timing of infusion reactions (IR) children who received rapid (1-h) vs. standard (2-h) IFX infusions. Methods retrospective cohort included patients 4-18 years old, treated between January 2006 - November 2021 at two tertiary centres (AMC VUmc) Amsterdam, Netherlands. The AMC protocol was adjusted from a 1-h post-infusion observation period July 2019, whereas VUmc only were administered without period. After merging both departments 2022, allocated primary outcome acute IR amongst Secondary outcomes timing, severity management IR. Results Totally, 297 (150 VUmc, 147 AMC) (221 Crohn’s disease; 65 ulcerative colitis; 11 IBD-unclassified) included, total 7500 maintenance IFX-infusions. No differences found receiving (16/115, 13.9% patients), (1/31, 3.2%) rates (11/151, 7.3%) (p= 0.105). difference (26/4383, 0.6% infusions) (9/3117, 0.3%) 0.083). Twenty-six 35 (74.3%) occurred during infusion, while nine (25.7%). All mild, requiring no intervention or oral medication. Conclusion did not result an increased compared that mild. Our resulted adjustment for all patients.
منابع مشابه
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
BACKGROUND AND AIMS This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated with the drug over a 14-year period. METHODS The medical records of 734 patients with IBD treated with infliximab and 666 control patients not treated with infliximab were reviewed for adverse events. The time of onset and outcome, severity and concomitant medi...
متن کاملAccelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
AIM To study the safety and effectiveness associated with accelerated infliximab infusion protocols in patients with inflammatory bowel disease (IBD). METHODS Original protocols and infusion rates were developed for the administration of infliximab over 90-min and 60-min. Then the IBD patients on stable maintenance infliximab therapy were offered accelerated infusions. To be eligible for the ...
متن کاملINFLAMMATORY BOWEL DISEASE Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study
Background and aims: The potentially high costs of care associated with inflammatory bowel disease (IBD) are recognised but we have little knowledge of the scale, profile, or determinants of these costs in the UK. This study aimed to describe costs of illness for a group of IBD patients and determine factors associated with increased healthcare costs. Setting: A university hospital serving a ta...
متن کاملHistopathological changes in anatomical distribution of inflammatory bowel disease in children: a retrospective cohort study
BACKGROUND Anatomical progression of pediatric inflammatory bowel disease is under-reported. The aim of this work was to examine possible changes in the anatomical distribution of IBD in pediatric patients at diagnosis and at follow up. METHODS In a retrospective cohort study, the medical records of children with inflammatory bowel disease were examined. Patients who had at least 2 endoscopic...
متن کاملSafety of infliximab in patients suffering from inflammatory bowel disease.
Accessible online at: www.karger.com/dig Tumor necrosis factor-· (TNF-·) is a central cytokine in the inflammatory process associated with Crohn’s disease (CD). Infliximab, a chimeric IgG1 antibody directed against soluble and membrane-bound TNF-·, has shown efficacy both in luminal and fistulizing CD. It was approved in October 1998 by the US Food and Drug Administration for the treatment of m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Crohn's and Colitis
سال: 2023
ISSN: ['1876-4479', '1873-9946']
DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0803